Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported Total Revenue of $263.50 million for fiscal year 2025.
IOVANCE BIOTHERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $263.50M +60.6% |
$164.07M +13699.0% |
$1.19M | — | — | — |
| Revenue (ASC 606) | $263.50M +60.6% |
$164.07M +13699.0% |
$1.19M | — | — | — |
| Net Income | -$390.98M -5.1% |
-$372.18M +16.2% |
-$444.04M -12.2% |
-$395.89M -15.7% |
-$342.25M -31.8% |
-$259.58M -31.4% |
| Diluted EPS | -$1.09 +14.8% |
-$1.28 +32.3% |
-$1.89 +24.1% |
-$2.49 -11.7% |
-$2.23 -18.6% |
-$1.88 -18.2% |
| Total Assets | $913.17M +0.3% |
$910.43M +16.7% |
$780.35M +17.5% |
$663.98M -14.6% |
$777.33M +1.2% |
$768.46M +123.0% |
| Cash and Equivalents | $163.08M +41.0% |
$115.69M +0.7% |
$114.89M -50.4% |
$231.73M +196.2% |
$78.23M +16.2% |
$67.33M +382.0% |
| Stockholders Equity | $698.58M -1.7% |
$710.40M +21.5% |
$584.61M +17.0% |
$499.64M -19.6% |
$621.66M -5.3% |
$656.50M +119.6% |
| R&D Expense | $300.27M +8.7% |
$276.23M -17.1% |
$333.19M +13.0% |
$294.78M +13.8% |
$259.04M +28.4% |
$201.73M +21.5% |
| Operating Income | -$403.36M -2.0% |
-$395.28M +14.2% |
-$460.56M -15.5% |
-$398.88M -16.4% |
-$342.70M -30.8% |
-$261.94M -26.6% |
| Shares Outstanding | 411.94M +35.0% |
305.25M +19.2% |
256.14M +36.4% |
187.81M +19.6% |
157.00M +6.2% |
147.87M +17.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $67.45M | +15.2% | +12.5% |
| Revenue (ASC 606) | September 30, 2025 | $67.45M | +15.2% | +12.5% |
| Net Income | September 30, 2025 | -$91.25M | -9.2% | +18.3% |
| Diluted EPS | June 30, 2025 | -$0.33 | +2.9% | +8.3% |
| Total Assets | September 30, 2025 | $904.95M | -8.7% | -0.3% |
| Cash and Equivalents | September 30, 2025 | $158.13M | -3.7% | +19.4% |
| Stockholders Equity | September 30, 2025 | $702.29M | -9.2% | +0.5% |
| R&D Expense | September 30, 2025 | $75.17M | +12.1% | -5.3% |
| Operating Income | September 30, 2025 | -$94.90M | -6.6% | +16.6% |
| Shares Outstanding | September 30, 2025 | 385.46M | +26.5% | +12.7% |
- IOVANCE BIOTHERAPEUTICS, INC. reported Total Revenue of $263.50 million for fiscal year 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +60.6% in Total Revenue compared to the prior fiscal year.
- IOVANCE BIOTHERAPEUTICS, INC. reported Revenue (ASC 606) of $263.50 million for fiscal year 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +60.6% in Revenue (ASC 606) compared to the prior fiscal year.
- IOVANCE BIOTHERAPEUTICS, INC. reported Net Income of -$390.98 million for fiscal year 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed a decrease of -5.1% in Net Income compared to the prior fiscal year.
- IOVANCE BIOTHERAPEUTICS, INC. reported Diluted EPS of $1.09 per share (loss) for fiscal year 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +14.8% in Diluted EPS compared to the prior fiscal year.
- IOVANCE BIOTHERAPEUTICS, INC. reported Total Assets of $913.17 million for fiscal year 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +0.3% in Total Assets compared to the prior fiscal year.
- IOVANCE BIOTHERAPEUTICS, INC. reported Cash and Equivalents of $163.08 million for fiscal year 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +41.0% in Cash and Equivalents compared to the prior fiscal year.
- IOVANCE BIOTHERAPEUTICS, INC. reported Stockholders Equity of $698.58 million for fiscal year 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed a decrease of -1.7% in Stockholders Equity compared to the prior fiscal year.
- IOVANCE BIOTHERAPEUTICS, INC. reported R&D Expense of $300.27 million for fiscal year 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +8.7% in R&D Expense compared to the prior fiscal year.
- IOVANCE BIOTHERAPEUTICS, INC. reported Operating Income of -$403.36 million for fiscal year 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed a decrease of -2.0% in Operating Income compared to the prior fiscal year.
- IOVANCE BIOTHERAPEUTICS, INC. reported Shares Outstanding of 411.94 million shares for fiscal year 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +35.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: